The bull case for MPLX, Republic Services, and Brookfield Infrastructure: pricing power may help offset inflation, with MPLX ...
Analyst rates American Savings Bank a Hold: 1.99x tangible book and Hawaii risks weigh on shares at $21.13; $18.75-$19.00 ...
Analyst rates Summit Midstream a Strong Buy as 2026 EBITDA guidance rises 4%; deleveraging could support share appreciation ...
Over the first 9 months of the calendar year, UGI faced headwinds from warmer weather and its non-core LPG divestitures. The ...
Analyst rates Enovix a Hold: its smartphone exit shifts focus to drone batteries, while higher odds of substantial near-term ...
Analyst rates Infineon a Hold: near €50, shares exceed the €37 target and offer insufficient risk-adjusted upside at 18.2x ...
Analyst rates Intuit a Hold: at $341.70, shares offer little margin of safety to $385 fair value, with higher FY2027 taxes ...
Analyst rates Nvidia a Strong Buy: the sell-off after Huang's exit looks overdone at 17.5x forward earnings through fiscal ...
Oil prices steady below $96 for Brent as Middle East attacks revive shipping risks, while the IEA sees a 2 million b/d supply ...
BlackRock Advantage International Fund gained 0.18% in Q3 2026, trailing its benchmark as sentiment insights weighed. Read ...
First Eagle Global Balanced Fund gained 0.32% in Q3 2026 as rates surged and AI dominated. Read the full portfolio review and ...
Ideaya Biosciences selects IDE101, a preclinical drug candidate for cancers lacking CDKN2A, and aims to seek U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results